📰 Boxed Warning News

Page 50 - Boxed Warning News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Boxed Warning. Real-time updates on events, politics, business and more.

Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies - Press Release

March 26, 2022

New England Journal of Medicine published OLUMIANT 36-week alopecia areata data today INDIANAPOLIS, March 26, 2022 /PRNewswire/ -- Adults with severe

United States Eli Lilly Brett King European Academy Of Dermatology Yale School Of Medicine Drug Administration

Source: wiredprnews.com

Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies

March 26, 2022

New England Journal of Medicine published OLUMIANT 36-week alopecia areata data today INDIANAPOLIS, March 26, 2022 /PRNewswire/ -- Adults with sev...

United States Catalina Loveman Kevin Hern Christine Chiou Marlo Scott Eli Lilly

Source: businessinsider.com

Heron Therapeutics Secures Pass-through Payment Status for ZYNRELEF® from Centers for Medicare & Medicaid Services, Expanding Separate Reimbursement into the Hospital Outpatient Setting of Care

March 25, 2022

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing...

United Kingdom David Szekeres Centers For Medicare Medicaid Services Prnewswire Heron Therapeutics Inc European Commission Drug Administration

Source: prnewswire.com

Acacia Pharma Announces Chief Financial Officer Gary

March 23, 2022

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and...

United Kingdom Gary Gemignani Acacia Pharma Group Paion United Kingdom Market Abuse Regulation Chief Financial Officer

Source: globenewswire.com

Investegate |Acacia Pharma Group plc Announcements | Acacia Pharma Group plc: Acacia Pharma Announces Chief Financial Officer Gary Gemignani is to Leave the Company

March 23, 2022

Investegate announcements from Acacia Pharma Group plc, Acacia Pharma Announces Chief Financial Officer Gary Gemignani is to Leave the Company

United Kingdom Irina Koffler Frazer Hall Mike Bolinder Gary Gemignani Chris Van Raemdonck

Source: investegate.co.uk

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Ortho Dermatologics Will Present New Data at the 2022 American Academy of Dermatology Annual Meeting

March 22, 2022

/PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, one of the largest...

United States Lainie Keller Arthur Shannon Brodalumab Elewski Bausch Health Companies Inc World Health Organization

Source: prnewswire.com

Heron Therapeutics Announces Approval of ZYNRELEF® by Health Canada for the Management of Postoperative Pain

March 17, 2022

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing...

United Kingdom David Szekeres Prnewswire Heron Therapeutics Inc European Commission Drug Administration Exchange Commission

Source: prnewswire.com

Heron Therapeutics Announces Approval of ZYNRELEF® by Health Canada for the Management of Postoperative Pain

March 17, 2022

Heron Therapeutics Announces Approval of ZYNRELEF® by Health Canada for the Management of Postoperative Pain - read this article along with other careers information, tips and advice on BioSpace

United Kingdom David Szekeres Prnewswire Heron Therapeutics Inc European Commission Drug Administration Exchange Commission

Source: biospace.com

Heron Therapeutics : Announces Approval of ZYNRELEF® by Health Canada for the Management of Postoperative Pain - Form 8-K

March 17, 2022

Heron Therapeutics Announces Approval of ZYNRELEF® by Health Canada for the Management of Postoperative Pain - ZYNRELEF is the first and only extended-release local... | March 17, 2022

United Kingdom David Szekeres Prnewswire Heron Therapeutics Inc European Commission Drug Administration Exchange Commission

Source: marketscreener.com